Sonam N Shah1,2, Roseann S Gammal3,4, Mary G Amato5,3, Maryam Alobaidly3, Dariel Delos Reyes3, Sarah Hasan3, Diane L Seger6, Joel B Krier4,7, David W Bates5,6,7. 1. Department of Internal Medicine, Brigham and Women's Hospital, 41 Avenue of Louis Pasteur, Office 103, Boston, MA, 02115, USA. sonamnshah@gmail.com. 2. Department of Pharmacy Practice, MCPHS University School of Pharmacy, Boston, MA, USA. sonamnshah@gmail.com. 3. Department of Pharmacy Practice, MCPHS University School of Pharmacy, Boston, MA, USA. 4. Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. 5. Department of Internal Medicine, Brigham and Women's Hospital, 41 Avenue of Louis Pasteur, Office 103, Boston, MA, 02115, USA. 6. Clinical Quality Analysis, Partners Healthcare, Somerville, MA, USA. 7. Harvard Medical School, Boston, MA, USA.
Abstract
INTRODUCTION: Medication-related harm represents a significant issue for patient safety and quality of care. One strategy to avoid preventable adverse drug events is to utilize patient-specific factors such as pharmacogenomics (PGx) to individualize therapy. OBJECTIVE: We measured the number of patients enrolled in a health-system biobank with actionable PGx results who received relevant medications and assessed the incidence of adverse drug events (ADEs) that might have been prevented had the PGx results been used to inform prescribing. METHODS: Patients with actionable PGx results in the following four genes with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines were identified: HLA-A*31:01, HLA-B*15:02, TPMT, and VKORC1. The patients who received interacting medications (carbamazepine, oxcarbazepine, thiopurines, or warfarin) were identified, and electronic health records were reviewed to determine the incidence of potentially preventable ADEs. RESULTS: Of 36,424 patients with PGx results, 2327 (6.4%) were HLA-A*31:01 positive; 3543 (9.7%) were HLA-B*15:02 positive; 2893 (7.9%) were TPMT intermediate metabolizers; and 4249 (11.7%) were homozygous for the VKORC1 c.1639 G>A variant. Among patients positive for one of the HLA variants who received carbamazepine or oxcarbazepine (n = 92), four (4.3%) experienced a rash that warranted drug discontinuation. Among the TPMT intermediate metabolizers who received a thiopurine (n = 56), 11 (19.6%) experienced severe myelosuppression that warranted drug discontinuation. Among patients homozygous for the VKORC1 c.1639 G>A variant who received warfarin (n = 379), 85 (22.4%) experienced active bleeding and/or international normalized ratio (INR) > 5 that warranted drug discontinuation or dose reduction. CONCLUSION: Patients with actionable PGx results from a health-system biobank who received relevant medications experienced predictable ADEs. These ADEs may have been prevented if the patients' PGx results were available in the electronic health record with clinical decision support prior to prescribing.
INTRODUCTION: Medication-related harm represents a significant issue for patient safety and quality of care. One strategy to avoid preventable adverse drug events is to utilize patient-specific factors such as pharmacogenomics (PGx) to individualize therapy. OBJECTIVE: We measured the number of patients enrolled in a health-system biobank with actionable PGx results who received relevant medications and assessed the incidence of adverse drug events (ADEs) that might have been prevented had the PGx results been used to inform prescribing. METHODS: Patients with actionable PGx results in the following four genes with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines were identified: HLA-A*31:01, HLA-B*15:02, TPMT, and VKORC1. The patients who received interacting medications (carbamazepine, oxcarbazepine, thiopurines, or warfarin) were identified, and electronic health records were reviewed to determine the incidence of potentially preventable ADEs. RESULTS: Of 36,424 patients with PGx results, 2327 (6.4%) were HLA-A*31:01 positive; 3543 (9.7%) were HLA-B*15:02 positive; 2893 (7.9%) were TPMT intermediate metabolizers; and 4249 (11.7%) were homozygous for the VKORC1 c.1639 G>A variant. Among patients positive for one of the HLA variants who received carbamazepine or oxcarbazepine (n = 92), four (4.3%) experienced a rash that warranted drug discontinuation. Among the TPMT intermediate metabolizers who received a thiopurine (n = 56), 11 (19.6%) experienced severe myelosuppression that warranted drug discontinuation. Among patients homozygous for the VKORC1 c.1639 G>A variant who received warfarin (n = 379), 85 (22.4%) experienced active bleeding and/or international normalized ratio (INR) > 5 that warranted drug discontinuation or dose reduction. CONCLUSION: Patients with actionable PGx results from a health-system biobank who received relevant medications experienced predictable ADEs. These ADEs may have been prevented if the patients' PGx results were available in the electronic health record with clinical decision support prior to prescribing.
Authors: Nadine Shehab; Maribeth C Lovegrove; Andrew I Geller; Kathleen O Rose; Nina J Weidle; Daniel S Budnitz Journal: JAMA Date: 2016-11-22 Impact factor: 56.272
Authors: Simona Volpi; Carol J Bult; Rex L Chisholm; Patricia A Deverka; Geoffrey S Ginsburg; Howard J Jacob; Melpomeni Kasapi; Howard L McLeod; Dan M Roden; Marc S Williams; Eric D Green; Laura Lyman Rodriguez; Samuel Aronson; Larisa H Cavallari; Joshua C Denny; Lynn G Dressler; Julie A Johnson; Teri E Klein; J Steven Leeder; Micheline Piquette-Miller; Minoli Perera; Laura J Rasmussen-Torvik; Heidi L Rehm; Marylyn D Ritchie; Todd C Skaar; Nikhil Wagle; Richard Weinshilboum; Kristin W Weitzel; Robert Wildin; John Wilson; Teri A Manolio; Mary V Relling Journal: Clin Pharmacol Ther Date: 2018-03-30 Impact factor: 6.875
Authors: Dan M Roden; Howard L McLeod; Mary V Relling; Marc S Williams; George A Mensah; Josh F Peterson; Sara L Van Driest Journal: Lancet Date: 2019-08-05 Impact factor: 79.321
Authors: S L Van Driest; Y Shi; E A Bowton; J S Schildcrout; J F Peterson; J Pulley; J C Denny; D M Roden Journal: Clin Pharmacol Ther Date: 2013-11-19 Impact factor: 6.875
Authors: Elizabeth J Phillips; Chonlaphat Sukasem; Michelle Whirl-Carrillo; Daniel J Müller; Henry M Dunnenberger; Wasun Chantratita; Barry Goldspiel; Yuan-Tsong Chen; Bruce C Carleton; Alfred L George; Taisei Mushiroda; Teri Klein; Roseann S Gammal; Munir Pirmohamed Journal: Clin Pharmacol Ther Date: 2018-02-02 Impact factor: 6.875
Authors: Robert C Green; Jonathan S Berg; Wayne W Grody; Sarah S Kalia; Bruce R Korf; Christa L Martin; Amy L McGuire; Robert L Nussbaum; Julianne M O'Daniel; Kelly E Ormond; Heidi L Rehm; Michael S Watson; Marc S Williams; Leslie G Biesecker Journal: Genet Med Date: 2013-06-20 Impact factor: 8.822